



Letter to the Editor- San Francisco Chronicle  
September 14, 2011

The article, “Study: BPA, methylparaben block breast cancer drugs,” is of little relevance to consumers. It provokes fear based on a single study and ignores a government-funded study that indicates BPA would not be present in the body long enough to cause a cellular response to these cancer-fighting drugs.

Funded by the U.S. EPA, the study provides definitive evidence that even the highest exposure levels of BPA from food contact applications did not allow for it to be detected in the human blood stream. This is the first study to demonstrate how the body processes BPA - by metabolizing and clearing it efficiently and effectively from the body.

Given how quickly BPA is eliminated from our bodies, it is extremely unlikely that the substance could have any impact on breast cancer cells or the cancer drugs, as suggested in the article. Simply put, if BPA does not stay in the body, it cannot reach the cellular level, and as a result, cannot impact cellular response. Exposing human cancer cells directly to BPA in a lab clearly does not reflect the body’s normal metabolic processes based on oral exposure in humans, rendering the laboratory results interesting but of little practical relevance.